Tumor HRD status was determined by Miriad myChoice CDx testing, which is designed based on germline/somatic BRCA1/2 mutations and/or positive genomic instability scores using DNA isolated from formalin-fixed paraffin-embedded (FFPE) tumor tissues. The gene discussed is BRCA1; the disease is neoplasm.